Abstract
Background
EGFR exon 20 insertion (EGFR ex20ins) mutations account for about 10–12% of all EGFR-mutated tumors, which are usually associated with primary drug resistance to conventional EGFR-TKI therapy and worse survival outcomes, and are currently a major problem for clinicians in clinical management. In recent years, with the rapid improvement of sequencing technology and careful review of clinical data, investigators have gained a deeper understanding and clearer cognition of the clinicopathological features and molecular mechanisms of these EGFR ex20ins mutations.
Purpose
The aim of this study was to systemically review the molecular structure and clinical characteristics of EGFR ex20ins mutations, and focus on summarizing the latest data of emerging therapies (including novel small-molecule EGFR-TKI drugs, specific monoclonal antibodies, novel drugs targeting other mechanisms, and immunotherapy) for those patients.
Conclusion
Advances in overcoming these systemic challenges have greatly accelerated the development of new drugs targeting EGFR ex20ins, and are committed to designing more rational combination therapies to overcome or delay the emergence of drug resistance, ultimately improve the prognosis of such uncommon mutant populations.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Arcila ME, Nafa K, Chaft JE et al (2013) EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics. Mol Cancer Ther 12(2):220–229. https://doi.org/10.1158/1535-7163.Mct-12-0620 (PMID:23371856)
Beau-Faller M, Prim N, Ruppert AM et al (2014) Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network. Ann Oncol 25(1):126–131. https://doi.org/10.1093/annonc/mdt418 (PMID:24285021)
Cardona AF, Rojas L, Zatarain-Barrón ZL et al (2018) EGFR exon 20 insertion in lung adenocarcinomas among Hispanics (geno1.2-CLICaP). Lung Cancer 125:265–272. https://doi.org/10.1016/j.lungcan.2018.10.007 (PMID:30429031)
Cha MY, Lee KO, Kim M et al (2012) Antitumor activity of HM781-36B, a highly effective pan-HER inhibitor in erlotinib-resistant NSCLC and other EGFR-dependent cancer models. Int J Cancer 130(10):2445–2454. https://doi.org/10.1002/ijc.26276 (PMID:21732342)
Chen K, Cheng G, Zhang F et al (2020) PD-L1 expression and T cells infiltration in patients with uncommon EGFR-mutant non-small cell lung cancer and the response to immunotherapy. Lung Cancer 142:98–105
Chen K, Pan G, Cheng G et al (2021) Immune microenvironment features and efficacy of PD‐1/PD‐L1 blockade in non‐small cell lung cancer patients with EGFR or HER2 exon 20 insertions. Thorac Cancer 12:218–226 (PMID:33210451)
Cho JH, Lim SH, An HJ et al (2020) Osimertinib for patients with non-small-cell lung cancer harboring uncommon EGFR mutations: a multicenter, open-label, phase II trial (KCSG-LU15-09). J Clin Oncol 38(5):488–495. https://doi.org/10.1200/jco.19.00931 (PMID:31825714)
Codony-Servat J, Codony-Servat C, Viteri S et al (2019) Hsp90 inhibitors enhance the antitumoral effect of osimertinib and overcome osimertinib resistance in non-small cell cell lung cancer cell models. Ann Oncol 30:v10–v11
Drilon A, Lin JJ, Filleron T et al (2018) Frequency of brain metastases and multikinase inhibitor outcomes in patients with RET-rearranged lung cancers. J Thorac Oncol 13(10):1595–1601. https://doi.org/10.1016/j.jtho.2018.07.004 (PMID:30017832)
Eck MJ, Yun CH (2010) Structural and mechanistic underpinnings of the differential drug sensitivity of EGFR mutations in non-small cell lung cancer. Biochim Biophys Acta 1804(3):559–566. https://doi.org/10.1016/j.bbapap.2009.12.010 (PMID:20026433)
Estrada-bernal A, Doak AE, Le AT, Zhu H, Chen N, Silva S et al (2018) Abstract A157: antitumor activity of tarloxotinib, a hypoxia-activated EGFR TKI, in patient-derived lung cancer cell lines harboring EGFR exon 20 insertions. Mol Cancer Ther 17:A157
Estrada-Bernal A, Le AT, Doak AE et al (2021) Tarloxotinib is a hypoxia-activated pan-HER kinase inhibitor active against a broad range of HER-family oncogenes. Clin Cancer Res 27(5):1463–1475. https://doi.org/10.1158/1078-0432.Ccr-20-3555 (PMID:33355298)
Fang W, Huang Y, Hong S et al (2019a) EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer. BMC Cancer 19(1):595. https://doi.org/10.1186/s12885-019-5820-0 (PMID:31208370)
Fang W, Huang Y, Gan J et al (2019b) A patient with EGFR exon 20 insertion-mutant non-small cell lung cancer responded to osimertinib plus cetuximab combination therapy. J Thorac Oncol 14(9):e201–e202. https://doi.org/10.1016/j.jtho.2019.04.013 (PMID:31445736)
Floc’h N, Martin MJ, Riess JW et al (2018) Antitumor activity of osimertinib, an irreversible mutant-selective EGFR tyrosine kinase inhibitor, in NSCLC harboring EGFR Exon 20 insertions. Mol Cancer Ther 17(5):885–896. https://doi.org/10.1158/1535-7163.Mct-17-0758 (PMID:29483211)
Forbes SA, Beare D, Boutselakis H et al (2017) COSMIC: somatic cancer genetics at high-resolution. Nucleic Acids Res 45(D1):D777-d783. https://doi.org/10.1093/nar/gkw1121 (PMID:27899578)
Garcia-Carbonero R, Carnero A, Paz-Ares L (2013) Inhibition of HSP90 molecular chaperones: moving into the clinic. Lancet Oncol 14(9):e358–e369. https://doi.org/10.1016/s1470-2045(13)70169-4 (PMID:23896275)
Gonzalvez F, Zhu X, Huang WS et al (2016) Abstract 2644: AP32788, a potent, selective inhibitor of EGFR and HER2 oncogenic mutants, including exon 20 insertions, in preclinical models. Can Res 76(14 Supplement):2644–2644
Gonzalvez F, Vincent S, Baker TE et al (2021) Mobocertinib (TAK-788): a targeted inhibitor of EGFR exon 20 insertion mutants in non-small cell lung cancer. Cancer Discov 11(7):1672–1687. https://doi.org/10.1158/2159-8290.Cd-20-1683 (PMID:33632773)
Grugan KD, Dorn K, Jarantow SW et al (2017) Fc-mediated activity of EGFR x c-Met bispecific antibody JNJ-61186372 enhanced killing of lung cancer cells. Mabs 9(1):114–126. https://doi.org/10.1080/19420862.2016.1249079 (PMID:27786612)
Harrison PT, Huang PH (2018) Exploiting vulnerabilities in cancer signalling networks to combat targeted therapy resistance. Essays Biochem 62(4):583–593. https://doi.org/10.1042/ebc20180016 (PMID:30072489)
Hasako S, Terasaka M, Abe N et al (2018) TAS6417, a novel EGFR inhibitor targeting exon 20 insertion mutations. Mol Cancer Ther 17(8):1648–1658. https://doi.org/10.1158/1535-7163.Mct-17-1206 (PMID:29748209)
Hasegawa H, Yasuda H, Hamamoto J et al (2019) Efficacy of afatinib or osimertinib plus cetuximab combination therapy for non-small-cell lung cancer with EGFR exon 20 insertion mutations. Lung Cancer 127:146–152. https://doi.org/10.1016/j.lungcan.2018.11.039 (PMID:30642543)
Hastings K, Yu HA, Wei W et al (2019) EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small cell lung cancer. Ann Oncol 30(8):1311–1320
Haura EB, Cho BC, Lee JS et al (2019) JNJ-61186372 (JNJ-372), an EGFR-cMet bispecific antibody, in EGFR-driven advanced non-small cell lung cancer (NSCLC). J Clin Oncol 37(15_suppl):9009–9009
Heymach J, Negrao M, Robichaux J et al (2018) OA02.06 a phase II trial of poziotinib in EGFR and HER2 exon 20 mutant non-small cell lung cancer (NSCLC). J Thorac Oncol 13(10):S323–S324
Hirano T, Yasuda H, Tani T et al (2015) In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer. Oncotarget 6(36):38789–38803. https://doi.org/10.18632/oncotarget.5887 (PMID:26515464)
Horn L, Lin HM, Padda SK et al (2020) Indirect comparison of TAK-788 vs real-world data outcomes in refractory non-small cell lung cancer (NSCLC) with EGFR exon 20 insertions. J Clin Oncol 38(15_suppl):9580–9580
Jang J, Son J, Park E et al (2018) Discovery of a highly potent and broadly effective epidermal growth factor receptor and HER2 exon 20 insertion mutant inhibitor. Angew Chem Int Ed Engl 57(36):11629–11633. https://doi.org/10.1002/anie.201805187 (PMID:29978938)
Janne PA, Neal JW, Camidge DR et al (2019) Antitumor activity of TAK-788 in NSCLC with EGFR exon 20 insertions. J Clin Oncol 37(15_suppl):9007–9007
Jorge SE, Kobayashi SS, Costa DB (2014) Epidermal growth factor receptor (EGFR) mutations in lung cancer: preclinical and clinical data. Braz J Med Biol Res 47(11):929–939. https://doi.org/10.1590/1414-431x20144099 (PMID:25296354)
Jorge SE, Lucena-Araujo AR, Yasuda H et al (2018) EGFR exon 20 insertion mutations display sensitivity to Hsp90 inhibition in preclinical models and lung adenocarcinomas. Clin Cancer Res 24(24):6548–6555. https://doi.org/10.1158/1078-0432.Ccr-18-1541 (PMID:30154228)
Jorge SE, Lucena-Araujo AR, Yasuda H et al (2020) Correction: EGFR exon 20 insertion mutations display sensitivity to Hsp90 inhibition in preclinical models and lung adenocarcinomas. Clin Cancer Res 26(9):2277–2277
Kapulnik Y, Douds DD (2000) Hormonal balance in plants during colonization by mycorrhizal fungi. Springer Neth Chapter 12:263–285. https://doi.org/10.1007/978-94-017-0776-3
Kim TM, Ock CY, Kim M et al (2019) 1529PPhase II study of osimertinib in NSCLC patients with EGFR exon 20 insertion mutation: a multicenter trial of the Korean Cancer Study Group (LU17–19). Ann Oncol 30(Supplement_5):v628
Kobayashi Y, Mitsudomi T (2016) Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy. Cancer Sci 107(9):1179–1186. https://doi.org/10.1111/cas.12996 (PMID:27323238)
Koga T, Kobayashi Y, Tomizawa K et al (2018) Activity of a novel HER2 inhibitor, poziotinib, for HER2 exon 20 mutations in lung cancer and mechanism of acquired resistance: an in vitro study. Lung Cancer 126:72–79. https://doi.org/10.1016/j.lungcan.2018.10.019 (PMID:30527195)
Kuiper JL, Hashemi SM, Thunnissen E et al (2016) Non-classic EGFR mutations in a cohort of Dutch EGFR-mutated NSCLC patients and outcomes following EGFR-TKI treatment. Br J Cancer 115(12):1504–1512. https://doi.org/10.1038/bjc.2016.372 (PMID:27875527)
Lau SCM, Fares AF, Le LW et al (2021) Subtypes of EGFR- and HER2-mutant metastatic NSCLC influence response to immune checkpoint inhibitors. Clin Lung Cancer. https://doi.org/10.1016/j.cllc.2020.12.015 (PMID:33582070)
Le X, Goldman JW, Clarke JM et al (2020) Poziotinib shows activity and durability of responses in subgroups of previously treated EGFR exon 20 NSCLC patients. J Clin Oncol 38(15_suppl):9514–9514
Leduc C, Merlio JP, Besse B et al (2017) Clinical and molecular characteristics of non-small-cell lung cancer (NSCLC) harboring EGFR mutation: results of the nationwide French Cooperative Thoracic Intergroup (IFCT) program. Ann Oncol 28(11):2715–2724. https://doi.org/10.1093/annonc/mdx404 (PMID:28945865)
Lee Y, Kim TM, Kim DW et al (2019) Preclinical modeling of osimertinib for NSCLC with EGFR exon 20 insertion mutations. J Thorac Oncol 14(9):1556–1566. https://doi.org/10.1016/j.jtho.2019.05.006 (PMID:31108249)
Li Y, Xu H, Su S et al (2017) Clinical validation of a highly sensitive assay to detect EGFR mutations in plasma cell-free DNA from patients with advanced lung adenocarcinoma. PLoS ONE 12(8):e0183331. https://doi.org/10.1371/journal.pone.0183331 (PMID:28829813)
Lin L, Wu X, Yan S et al (2020) Response to afatinib in a patient with NSCLC harboring novel EGFR exon 20 insertion mutations. Onco Targets Ther 13:9753–9757. https://doi.org/10.2147/ott.S268694 (PMID:33061454)
Liu SV, Villaruz LC, Lee VHF et al (2020) LBA61 first analysis of RAIN-701: study of tarloxotinib in patients with non-small cell lung cancer (NSCLC) EGFR Exon 20 insertion, HER2-activating mutations and other solid tumours with NRG1/ERBB gene fusions. Ann Oncol 31:S1189. https://doi.org/10.1016/j.annonc.2020.08.2294
Maemondo M, Inoue A, Kobayashi K et al (2010) Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362(25):2380–2388. https://doi.org/10.1056/NEJMoa0909530 (PMID:20573926)
Masuzawa K, Yasuda H, Hamamoto J et al (2017) Characterization of the efficacies of osimertinib and nazartinib against cells expressing clinically relevant epidermal growth factor receptor mutations. Oncotarget 8(62):105479–105491. https://doi.org/10.18632/oncotarget.22297 (PMID:29285266)
Metro G, Baglivo S, Bellezza G et al (2021) Sensitivity to immune checkpoint blockade in advanced non-small cell lung cancer patients with egfr exon 20 insertion mutations. Genes 12(5):679
Midha A, Dearden S, Mccormack R (2015) EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII). Am J Cancer Res 5(9):2892–2911 (PMID:26609494)
Moores SL, Chiu ML, Bushey BS et al (2016) A novel bispecific antibody targeting EGFR and cMet is effective against EGFR inhibitor-resistant lung tumors. Cancer Res 76(13):3942–3953. https://doi.org/10.1158/0008-5472.Can-15-2833 (PMID:27216193)
Naidoo J, Sima CS, Rodriguez K et al (2015) Epidermal growth factor receptor exon 20 insertions in advanced lung adenocarcinomas: clinical outcomes and response to erlotinib. Cancer 121(18):3212–3220. https://doi.org/10.1002/cncr.29493 (PMID:26096453)
Neal J, Doebele R, Riely G et al (2018) P1.13-44 safety, PK, and preliminary antitumor activity of the oral EGFR/HER2 exon 20 inhibitor TAK-788 in NSCLC. J Thorac Oncol 13(10):S599
Negrao MV, Reuben A, Robichaux JP et al (2018) Association of EGFR and HER-2 exon 20 mutations with distinct patterns of response to immune checkpoint blockade in non-small cell lung cancer. J Clin Oncol 36(15_suppl):9052–9052
Neijssen J, Cardoso RMF, Chevalier KM et al (2021) Discovery of amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR and MET. J Biol Chem 296:100641. https://doi.org/10.1016/j.jbc.2021.100641 (PMID:33839159)
Nishino M, Suda K, Koga T et al (2021) Activity of tarloxotinib-E in cells with EGFR exon-20 insertion mutations and mechanisms of acquired resistance. Thorac Cancer 12(10):1511–1516. https://doi.org/10.1111/1759-7714.13931 (PMID:33710795)
Noronha V, Choughule A, Patil VM et al (2017) Epidermal growth factor receptor exon 20 mutation in lung cancer: types, incidence, clinical features and impact on treatment. Onco Targets Ther 10:2903–2908. https://doi.org/10.2147/ott.S133245 (PMID:28652772)
O’kane GM, Bradbury PA, Feld R et al (2017) Uncommon EGFR mutations in advanced non-small cell lung cancer. Lung Cancer 109:137–144. https://doi.org/10.1016/j.lungcan.2017.04.016 (PMID:28577943)
Oxnard GR, Lo PC, Nishino M et al (2013) Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions. J Thorac Oncol 8(2):179–184. https://doi.org/10.1097/JTO.0b013e3182779d18 (PMID:23328547)
Pan Y, Zhang Y, Li Y et al (2014) Prevalence, clinicopathologic characteristics, and molecular associations of EGFR exon 20 insertion mutations in East Asian patients with lung adenocarcinoma. Ann Surg Oncol 21(Suppl 4):S490–S496. https://doi.org/10.1245/s10434-013-3452-1 (PMID:24419753)
Park K, Tan EH, O’byrne K et al (2016) Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. Lancet Oncol 17(5):577–589. https://doi.org/10.1016/s1470-2045(16)30033-x (PMID:27083334)
Park K, Ahn M, Lee S et al (2018) OA10.06 a first-in-human phase 1 trial of the EGFR-cMET bispecific antibody JNJ-61186372 in patients with advanced non-small cell lung cancer (NSCLC). J Thorac Oncol 13(10):S344–S345
Park S, Lee MH, Seong M et al (2020a) A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy. Ann Oncol 31(10):1397–1404. https://doi.org/10.1016/j.annonc.2020.06.017 (PMID:32634610)
Park K, John T, Kim SW et al (2020b) Amivantamab (JNJ-61186372), an anti-EGFR-MET bispecific antibody, in patients with EGFR exon 20 insertion (exon20ins)-mutated non-small cell lung cancer (NSCLC). J Clin Oncol 38(15_suppl):9512–9512
Piotrowska Z, Costa DB, Oxnard GR et al (2018) Activity of the Hsp90 inhibitor luminespib among non-small cell lung cancers harboring EGFR exon 20 insertions. Ann Oncol 29:2092–2097
Piotrowska Z, Wang Y, Sequist LV et al (2020a) ECOG-ACRIN 5162: A phase II study of osimertinib 160 mg in NSCLC with EGFR exon 20 insertions. J Clin Oncol 38(15_suppl):9513–9513
Piotrowska Z, Nguyen D, Koczywas M et al (2020b) 1345P Preliminary safety and activity of CLN-081 in NSCLC with EGFR exon 20 insertion mutations (Ins20). Ann Oncol 31:S862–S863
Piotrowska Z, Yu HA, Yang JC-H et al (2021) Safety and activity of CLN-081 (TAS6417) in NSCLC with EGFR exon 20 insertion mutations (Ins20). In: Presented at: American Society of clinical oncology annual meeting; June 4–8, 2021; Virtual. Abstract 9077. https://www.cancernetwork.com/view/first-in-human-trial-of-cln-081-in-egfr-ex-20-nsclc-shows-early-promise
Piper-Vallillo A, Rotow JK, Aredo JV et al (2020) High-dose osimertinib for CNS progression in EGFR+ non-small cell lung cancer (NSCLC): a multi-institutional experience. J Clin Oncol 38(15_suppl):9586–9586
Postel M, Roosen A, Laurent-Puig P et al (2018) Droplet-based digital PCR and next generation sequencing for monitoring circulating tumor DNA: a cancer diagnostic perspective. Expert Rev Mol Diagn 18(1):7–17. https://doi.org/10.1080/14737159.2018.1400384 (PMID:29115895)
Puri N, Salgia R (2008) Synergism of EGFR and c-Met pathways, cross-talk and inhibition, in non-small cell lung cancer. J Carcinog 7:9. https://doi.org/10.4103/1477-3163.44372 (PMID:19240370)
Ramalingam SS, Vansteenkiste J, Planchard D et al (2020) Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med 382(1):41–50. https://doi.org/10.1056/NEJMoa1913662 (PMID:31751012)
Regales L, Gong Y, Shen R et al (2009) Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer. J Clin Investig 119(10):3000–3010. https://doi.org/10.1172/jci38746 (PMID:19759520)
Riely GJ, Neal JW, Camidge DR et al (2021) Activity and safety of mobocertinib (TAK-788) in previously treated non-small cell lung cancer with egfr exon 20 insertion mutations from a phase I/II trial. Cancer Discov 11(7):1688–1699. https://doi.org/10.1158/2159-8290.Cd-20-1598 (PMID:33632775)
Riess JW, Gandara DR, Frampton GM et al (2018) Diverse EGFR exon 20 insertions and co-occurring molecular alterations identified by comprehensive genomic profiling of NSCLC. J Thorac Oncol 13(10):1560–1568. https://doi.org/10.1016/j.jtho.2018.06.019 (PMID:29981927)
Riess JW, Reckamp KL, Frankel P et al (2021) Erlotinib and onalespib lactate focused on EGFR exon 20 insertion non-small cell lung cancer (NSCLC): a california cancer consortium phase I/II Trial (NCI 9878). Clin Lung Cancer. https://doi.org/10.1016/j.cllc.2021.05.001 (PMID:34140248)
Robichaux JP, Elamin YY, Tan Z et al (2018) Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer. Nat Med 24(5):638–646. https://doi.org/10.1038/s41591-018-0007-9 (PMID:29686424)
Robichaux JP, Elamin YY, Vijayan RSK et al (2019) Pan-cancer landscape and analysis of ERBB2 mutations identifies poziotinib as a clinically active inhibitor and enhancer of T-DM1 activity. Cancer Cell 36(4):444-457.e7. https://doi.org/10.1016/j.ccell.2019.09.001 (PMID:31588020)
Ruan Z, Kannan N (2018) Altered conformational landscape and dimerization dependency underpins the activation of EGFR by αC-β4 loop insertion mutations. Proc Natl Acad Sci USA 115(35):E8162-e8171. https://doi.org/10.1073/pnas.1803152115 (PMID:30104348)
Russo A, Franchina T, Ricciardi G et al (2019) Heterogeneous responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with uncommon EGFR mutations: new insights and future perspectives in this complex clinical scenario. Int J Mol Sci. https://doi.org/10.3390/ijms20061431 (PMID:30901844)
Satapathy S, Singh V, Nambirajan A et al (2021) EGFR mutation testing on plasma and urine samples: a pilot study evaluating the value of liquid biopsy in lung cancer diagnosis and management. Curr Probl Cancer. https://doi.org/10.1016/j.currproblcancer.2021.100722 (PMID:33712318)
Sequist LV, James Chih-Hsin Y, Nobuyuki Y et al (2019) Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 31(27):3327–3334
Shigematsu H, Lin L, Takahashi T et al (2005) Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 97(5):339–346. https://doi.org/10.1093/jnci/dji055 (PMID:15741570)
Shimamura T, Lowell AM, Engelman JA et al (2005) Epidermal growth factor receptors harboring kinase domain mutations associate with the heat shock protein 90 chaperone and are destabilized following exposure to geldanamycins. Cancer Res 65(14):6401–6408. https://doi.org/10.1158/0008-5472.Can-05-0933 (PMID:16024644)
Trepel J, Mollapour M, Giaccone G et al (2010) Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer 10(8):537–549. https://doi.org/10.1038/nrc2887 (PMID:20651736)
Tsigelny IF, Wheler JJ, Greenberg JP et al (2015) Molecular determinants of drug-specific sensitivity for epidermal growth factor receptor (EGFR) exon 19 and 20 mutants in non-small cell lung cancer. Oncotarget 6(8):6029–6039. https://doi.org/10.18632/oncotarget.3472 (PMID:25760241)
Tu HY, Ke EE, Yang JJ et al (2017) A comprehensive review of uncommon EGFR mutations in patients with non-small cell lung cancer. Lung Cancer 114:96–102. https://doi.org/10.1016/j.lungcan.2017.11.005 (PMID:29173773)
Udagawa H, Hasako S, Ohashi A et al (2019) TAS6417/CLN-081 is a pan-mutation-selective EGFR tyrosine kinase inhibitor with a broad spectrum of preclinical activity against clinically relevant EGFR mutations. Mol Cancer Res 17(11):2233–2243. https://doi.org/10.1158/1541-7786.Mcr-19-0419 (PMID:31467113)
Urbán L, Dóczi R, Vodicska B et al (2021) Major clinical response to afatinib monotherapy in lung adenocarcinoma harboring EGFR exon 20 insertion mutation. Clin Lung Cancer 22(1):e112–e115. https://doi.org/10.1016/j.cllc.2020.09.005 (PMID:33082101)
Van Veggel B, De Langen AJ, Hashemi SMS et al (2018) Afatinib and cetuximab in four patients with EGFR exon 20 insertion-positive advanced NSCLC. J Thorac Oncol 13(8):1222–1226. https://doi.org/10.1016/j.jtho.2018.04.012 (PMID:29702285)
Van Veggel B, Madeira RSJFV, Hashemi SMS et al (2020) Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer. Lung Cancer 141:9–13. https://doi.org/10.1016/j.lungcan.2019.12.013 (PMID:31926441)
Vasconcelos P, Gergis C, Viray H et al (2020) EGFR-A763_Y764insFQEA Is a unique exon 20 insertion mutation that displays sensitivity to approved and in-development lung cancer EGFR tyrosine kinase inhibitors. JTO Clin Res Rep. https://doi.org/10.1016/j.jtocrr.2020.100051 (PMID:34104899)
Vyse S, Huang PH (2019) Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer. Signal Transduct Target Ther 4:5. https://doi.org/10.1038/s41392-019-0038-9 (PMID:30854234)
Watanabe S, Minegishi Y, Yoshizawa H et al (2014) Effectiveness of gefitinib against non-small-cell lung cancer with the uncommon EGFR mutations G719X and L861Q. J Thorac Oncol 9(2):189–194. https://doi.org/10.1097/jto.0000000000000048 (PMID:24419415)
Wu JY, Yu CJ, Shih JY (2019) Effectiveness of treatments for advanced non-small-cell lung cancer with exon 20 insertion epidermal growth factor receptor mutations. Clin Lung Cancer 20(6):e620–e630. https://doi.org/10.1016/j.cllc.2019.06.018 (PMID:31327643)
Wu Y L, Cheng Y, Zhou X et al (2017) Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. Lancet Oncol 18:1454–1466 (PMID:28958502)
Xu CW, Wang WX, Wang D et al (2020) Pemetrexed-based chemotherapy for non-small-cell lung cancer patients with EGFR exon 20 insertion mutation: a multicenter study. Transl Lung Cancer Res 9(5):1853–1861. https://doi.org/10.21037/tlcr-20-382 (PMID:33209607)
Xu Y, Zhang L, Zhu L et al (2019) Abstract 3081: DZD9008, an oral, wild type selective EGFR inhibitor for the treatment of non-small-cell lung cancer with Exon20 insertion and other activating mutations. In: Proceedings: AACR annual meeting 2019 March 29–April 3, 2019 Atlanta, GA, 2019
Yang JC, Wu YL, Chan V et al (2014) Epidermal growth factor receptor mutation analysis in previously unanalyzed histology samples and cytology samples from the phase III Iressa Pan-ASia Study (IPASS). Lung Cancer 83(2):174–181. https://doi.org/10.1016/j.lungcan.2013.11.021 (PMID:24361280)
Yang M, Xu X, Cai J et al (2016) NSCLC harboring EGFR exon-20 insertions after the regulatory C-helix of kinase domain responds poorly to known EGFR inhibitors. Int J Cancer 139(1):171–176. https://doi.org/10.1002/ijc.30047 (PMID:26891175)
Yang G, Li J, Xu H et al (2020a) EGFR exon 20 insertion mutations in Chinese advanced non-small cell lung cancer patients: Molecular heterogeneity and treatment outcome from nationwide real-world study. Lung Cancer 145:186–194. https://doi.org/10.1016/j.lungcan.2020.03.014 (PMID:32336530)
Yang JCH, Kim SW, Kim DW et al (2020b) Osimertinib in patients with epidermal growth factor receptor mutation-positive non-small-cell lung cancer and leptomeningeal metastases: the BLOOM study. J Clin Oncol 38(6):538–547. https://doi.org/10.1200/jco.19.00457 (PMID:31809241)
Yang JC, Wang M, Mitchell P, Fang J, Nian W, Chiu CH, Zhou J, Zhao Y, Su WC, Camidge DR, Yang TY (2021) Preliminary safety and efficacy results from phase 1 studies of DZD9008 in NSCLC patients with EGFR Exon20 insertion mutations. ASCO. 10:1028–1043. https://doi.org/10.1200/JCO.2021.39.15_suppl.9008 (PMID: 34118178)
Yasuda H, Park E, Yun CH et al (2013) Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer. Sci Transl Med 5(216):216ra177. https://doi.org/10.1126/scitranslmed.3007205 (PMID:24353160)
Yun J, Lee SH, Kim SY et al (2020) Antitumor activity of amivantamab (JNJ-61186372), an EGFR-MET bispecific antibody, in diverse models of EGFR exon 20 insertion-driven NSCLC. Cancer Discov 10(8):1194–1209. https://doi.org/10.1158/2159-8290.Cd-20-0116 (PMID:32414908)
Zhang S, Jin S, Griffin C, Feng Z, Lin J, Baratta M, Brake R, Venkatakrishnan K, Gupta N (2021) Single-dose pharmacokinetics and tolerability of the oral epidermal growth factor receptor inhibitor mobocertinib (TAK-788) in healthy volunteers: low-fat meal effect and relative bioavailability of 2 capsule products. Clin Pharmacol Drug Dev 10:1028–1043 (PMID:34118178)
Zhou C, Ramalingam S, Li B et al (2021) OA04.03 mobocertinib in NSCLC With EGFR exon 20 insertions: results from EXCLAIM and pooled platinum-pretreated patient populations. J Thorac Oncol 16(3):S108
Zöchbauer-Müller S, Kaserer B, Prosch H et al (2020) Case report: afatinib treatment in a patient with NSCLC harboring a rare EGFR exon 20 mutation. Front Oncol 10:593852. https://doi.org/10.3389/fonc.2020.593852 (PMID:33575211)
Acknowledgements
This work was supported by grants from Jilin Provincial Science and Technology Department (20190303146SF).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
No potential conflicts of interest are disclosed.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Bai, R., Chen, X., Song, W. et al. Therapeutic exploration of uncommon EGFR exon 20 insertion mutations in advanced non-small cell lung cancer: breaking through brambles and thorns. J Cancer Res Clin Oncol 148, 163–176 (2022). https://doi.org/10.1007/s00432-021-03840-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-021-03840-y